Literature DB >> 11287590

The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.

S Aquaro1, P Menten, S Struyf, P Proost, J Van Damme, E De Clercq, D Schols.   

Abstract

The CC-chemokines RANTES, macrophage inflammatory protein 1alpha (MIP-1alpha), and MIP-1beta are natural ligands for the CC-chemokine receptor CCR5. MIP-1alpha, also known as LD78alpha, has an isoform, LD78beta, which was identified as the product of a nonallelic gene. The two isoforms differ in only 3 amino acids. LD78beta was recently reported to be a much more potent CCR5 agonist than LD78alpha and RANTES in inducing intracellular Ca2+ signaling and chemotaxis. CCR5 is expressed by human monocytes/macrophages (M/M) and represents an important coreceptor for macrophage-tropic, CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1) strains to infect the cells. We compared the antiviral activities of LD78beta and the other CC-chemokines in M/M. LD78beta at 100 ng/ml almost completely blocked HIV-1 replication, while at the same concentration LD78alpha had only weak antiviral activity. Moreover, when HIV-1 infection in M/M was monitored by a flow cytometric analysis using p24 antigen intracellular staining, LD78beta proved to be the most antivirally active of the chemokines. RANTES, once described as the most potent chemokine in inhibiting R5 HIV-1 infection, was found to be considerably less active than LD78beta. LD78beta strongly downregulated CCR5 expression in M/M, thereby explaining its potent antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287590      PMCID: PMC114186          DOI: 10.1128/JVI.75.9.4402-4406.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Chemokines and HIV replication.

Authors:  H Schmidtmayerova; B Sherry; M Bukrinsky
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

2.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

Review 3.  Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

Authors:  S Aquaro; C F Perno; E Balestra; J Balzarini; A Cenci; M Francesconi; S Panti; F Serra; N Villani; R Caliò
Journal:  J Leukoc Biol       Date:  1997-07       Impact factor: 4.962

4.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

5.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Authors:  G Simmons; P R Clapham; L Picard; R E Offord; M M Rosenkilde; T W Schwartz; R Buser; T N Wells; A E Proudfoot
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

6.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

7.  Localization of human immunodeficiency virus core antigen in term human placentas.

Authors:  C F Mattern; K Murray; A Jensen; H Farzadegan; J Pang; J F Modlin
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

8.  A model of human immunodeficiency virus encephalitis in scid mice.

Authors:  W R Tyor; C Power; H E Gendelman; R B Markham
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.

Authors:  A Amara; S L Gall; O Schwartz; J Salamero; M Montes; P Loetscher; M Baggiolini; J L Virelizier; F Arenzana-Seisdedos
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

10.  CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.

Authors:  L Wu; W A Paxton; N Kassam; N Ruffing; J B Rottman; N Sullivan; H Choe; J Sodroski; W Newman; R A Koup; C R Mackay
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  17 in total

1.  Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.

Authors:  Anthony R Geonnotti; Miroslawa Bilska; Xing Yuan; Christina Ochsenbauer; Tara G Edmonds; John C Kappes; Hua-Xin Liao; Barton F Haynes; David C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

2.  Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.

Authors:  Wendy E Walker; Sebastian Kurscheid; Samit Joshi; Charlie A Lopez; Gerald Goh; Murim Choi; Lydia Barakat; John Francis; Ann Fisher; Michael Kozal; Heidi Zapata; Albert Shaw; Richard Lifton; Richard E Sutton; Erol Fikrig
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.

Authors:  Miguel Stevens; Michela Pollicita; Christophe Pannecouque; Erik Verbeken; Oriana Tabarrini; Violetta Cecchetti; Stefano Aquaro; Carlo Federico Perno; Arnaldo Fravolini; Erik De Clercq; Dominique Schols; Jan Balzarini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 4.  Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease.

Authors:  R Colobran; E Pedrosa; L Carretero-Iglesia; M Juan
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

5.  Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission.

Authors:  Stephen Meddows-Taylor; Samantha L Donninger; Maria Paximadis; Diana B Schramm; Fiona S Anthony; Glenda E Gray; Louise Kuhn; Caroline T Tiemessen
Journal:  J Gen Virol       Date:  2006-07       Impact factor: 3.891

6.  Productive infection of primary macrophages with human herpesvirus 7.

Authors:  Y Zhang; L de Bolle; S Aquaro; A van Lommel; E De Clercq; D Schols
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

8.  CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder.

Authors:  Amanda Brown; Ned Sacktor; Karen Marder; Bruce Cohen; Giovanni Schifitto; Richard L Skolasky; Jason Creighton; Liping Guo; Justin C McArthur
Journal:  Curr Biomark Find       Date:  2012-01-01

9.  Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy.

Authors:  Tong Wang; Younong Xu; Haiying Zhu; Thomas Andrus; Sergei B Ivanov; Charlotte Pan; Jazel Dolores; Gregory C Dann; Michael Zhou; Dominic Forte; Zihuan Yang; Sarah Holte; Lawrence Corey; Tuofu Zhu
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

10.  Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population.

Authors:  M Paximadis; D B Schramm; G E Gray; G Sherman; A Coovadia; L Kuhn; C T Tiemessen
Journal:  Genes Immun       Date:  2012-11-15       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.